Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HCV RWE
- Sponsors AbbVie
- 23 Jun 2017 Status changed from active, no longer recruiting to completed.
- 05 May 2017 Planned End Date changed from 1 Sep 2017 to 19 Jun 2017.
- 05 May 2017 Planned primary completion date changed from 1 Sep 2017 to 19 Jun 2017.